



KONGERIKET NORGE
The Kingdom of Norway

REC'D 23 MAR 2005

WIPO

PCT

Bekreftelse på patentsøknad nr
Certification of patent application no

▽
20040953

► Det bekreftes herved at vedheftede dokument er nøyaktig utskrift/kopi av ovennevnte søknad, som opprinnelig inngitt 2004.03.04

► *It is hereby certified that the annexed document is a true copy of the above-mentioned application, as originally filed on 2004.03.04*


2005.03.04

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Line Reum

Line Reum
Saksbehandler



PATENTSTYRET®
Styret for det industrielle rettsvern

Søknad om patent

www.patentstyret.no



Ferdig utfylt skjema sendes til adressen nedenfor. Vennligst ikke heft sammen sidene.
Vi ber om at blankettene utfylles *maskinelt* eller ved bruk av *blokkbokstaver*. Skjema for
utfylling på datamaskin kan lastes ned fra **www.patentstyret.no**.

Søker Den som søker om patent blir også innehaver av en eventuell rettighet. Må fylles ut.

Foretakets navn (fornavn hvis søker er person):

Amersham Health AS

Etternavn (hvis søker er person):

☒ Kryss av hvis søker tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Nycoveien 1-2

Postboks 4220 Nydalen

Postnummer:

0401

Poststed:

Oslo

Land:

Norge

☐ Kryss av hvis flere søkere er angitt i
medfølgende skjema eller på eget ark.☐ Kryss av hvis søker(ne) utfører
20 årsverk eller mindre (se veiledning).**Kontaktinfo** Hvem skal Patentstyret henvende seg til? Oppgi telefonnummer og eventuell referanse.

Fornavn til kontaktperson for fullmektig eller søker:

Liv-Heidi

Etternavn:

Thoresen



Telefon:

23185472

Referanse (maks. 30 tegn):

PN0411-NO



Fvr. adresse til kontaktperson:

Amersham Health AS

Nycoveien 1-2, Postboks 4220 Nydalen

Postnummer:

0401

Poststed:

Oslo

Land:

Norge

Fullmektig Hvis du ikke har oppnevnt en fullmektig kan du gå til neste punkt.

Foretakets navn (fornavn hvis fullmektig er person):

Amersham Health AS

Etternavn (hvis fullmektig er person):

☒ Kryss av hvis fullmektig tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Nycoveien 1-2

Postboks 4220 Nydalen

Postnummer:

0401

Poststed:

Oslo

Land:

Norge

Oppfinner Oppfinneren skal alltid oppgis, selv om oppfinner og søker er samme person.

Oppfinnerens fornavn:

Dagfinn

Etternavn:

Løvhaug

☐ Kryss av hvis oppfinner tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Amersham Health AS

Nycoveien 1-2, Postboks 4220 Nydalen

Postnummer:

0401

Poststed:

Oslo

Land:

Norge

☐ Kryss av hvis flere oppfinnere er angitt i medfølgende skjema eller på eget ark.

ADRESSE


Postboks 8160 Dep.
Københavnsgaten 10
00333 Oslo

TELEFON

22 38 73 00
TELEFAXS
22 38 73 01

BANKGIRO

8276.01.00192
ORGANISASJONSNR.
971526157 MVA



PATENTSTYRET
Styret for det industrielle rettsvern

SØKNAD s. 1 av 2

FLERE SØKERE

FLERE OPPFINNERE

PRIORITETER

VEILEDNING

+47 23186019

2004-03-04

www.patentstyret.no



... søknad om patent

▼ Tittel: Gi en kort benevnelse eller tittel for oppfinnelsen (ikke over 256 tegn, inkludert mellomrom).

Tittel:
Pharmaceutical compounds

▼ PCT: Fylls bare ut hvis søknaden er en videreføring av en tidligere innlevert internasjonal søknad (PCT).

Inngivelsesdato (åååå.mm.dd):

Søknadsnummer:

PCT-søknadens dato og nummer:

PCT

/

▼ Prioritetskrav: Hvis du ikke har søkt om denne oppfinnelsen tidligere i et annet land eller i Norge kan du gå videre til neste punkt.

Prioritet kreves på grunnlag av tidligere innlevert søknad i Norge eller utlandet:

Inngivelsesdato (åååå.mm.dd):

Landkode:

Søknadsnummer:

Opplysninger om tidligere søknad. Ved flere krav skal tidligste prioritet angis her:

☐ Flere prioritetskrav er angitt i medfølgende skjema, eller på eget ark.

▼ Biologisk materiale: Fylls bare ut hvis oppfinnelsen omfatter biologisk materiale.

Søknaden omfatter biologisk materiale. Deponeringssted og nummer må oppgis:

Deposeringssted og nummer (benytt gjerne eget ark):

☐ Prøve av materiale skal bare utleveres til en særlig sakkyndig.

▼ Avdelt/utskilt: Hvis du ikke har søkt om patent i Norge tidligere kan du gå videre til neste punkt.

Søknaden er avdelt eller utskilt fra tidligere levert søknad i Norge:

☐ Avdelt søknad

Dato (åååå.mm.dd):

Søknadsnummer:

☐ Utskilt søknad

Informasjon om opprinnelig søknad/innsendt tilleggsmateriale

▼ Annet:

☒ Søknaden er også levert per telefaks.

Oppgi dato (åååå.mm.dd):

2004.03.04

☐ Jeg har fått utført forundersøkelse.

Oppgi nr (årstall - nummer - bokstav):

▶ Vedlegg: Angi hvilken dokumentasjon av oppfinnelsen du legger ved, samt andre vedlegg.

☒ Tegninger

Oppgi antall tegninger:

1

☒ Beskrivelse av oppfinnelsen

☒ Patentkrav

☒ Fullmaktsdokument(er)

☐ Sammenheng på norsk

☐ Overdragelsesdokument(er)

☐ Dokumentasjon av eventuelle prioritetskrav (prioritetsbevis)

☐ Erklæring om retten til oppfinnelsen

☐ Oversettelse av internasjonal søknad (kun hvis PCT-felt over er fylt ut)

☒ Annet: Sekvensliste

▶ Dato/underskrift: Sjekk at du har fylt ut punktene under «Søker», «Oppfinner» og «Vedlegg». Signer søknaden.

Sted og dato (blokkbokstaver):

Oslo, 4. mars 2004

Navn i blokkbokstaver:

Live-Heidi Thoresen

Signatur:

NB! Søknadsavgiften vil bli fakturert for alle søknader (dvs. at søknadsavgiften ikke skal følge søknaden).
Betalingsfrist er ca. 1 måned, se faktura.



PATENTSTYRET
Styret for det industrielle rettvern

SØKNAD s. 2 av 2

2004 -03- 04

PHARMACEUTICAL COMPOUNDS

Field of invention

The present invention relates to novel pharmaceuticals suitable for use in the treatment of heart failure, cardiac arrhythmia and other diseases where fibrosis is prominent and in the diagnosis of heart failure and other diseases where fibrosis is prominent. More specifically the invention relates to pharmaceuticals useful in treatment and diagnosis of diseases associated with the up-regulation of the Angiotensin II receptor, AT₁, and Angiotensin Converting Enzyme, ACE. The pharmaceuticals of the present invention are converted into its active form (i.e. the AT₁ targeting form) by cleavage by ACE *in vivo*.

Diseases, which can be detected by the use of imaging agents targeting the AT₁ receptor, are congestive heart failure (CHF), arteriosclerosis and other diseases and conditions where a fibrotic process is prominent.

The pharmaceuticals comprise a peptidic Angiotensin I (Ang I) analogue with an ACE cleavage site, further the pharmaceuticals comprises a group which can carry a diagnostically imageable moiety and an optional linker. After cleavage with ACE active pharmaceuticals comprising an Angiotensin II (Ang II) analogue, a group capable of carrying a diagnostically imageable moiety and an optional linker is formed. The imaging agent has affinity for the Angiotensin receptors, in particular for the Angiotensin II type 1 (AT₁) receptor.

Background of invention

Angiotensin II (Ang II) - the octapeptide (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) - is a pleiotropic vasoactive peptide that binds to two distinct receptors: the Ang II type 1 (AT₁) and type 2 (AT₂) receptors. Activation of the renin-angiotensin-aldosterone system (RAAS) results in vascular hypertrophy, vasoconstriction, salt and water retention, and hypertension. These effects are mediated predominantly by AT₁ receptors. Other Ang II-mediated effects, including cell death, vasodilation, and natriuresis, are mediated by AT₂ receptor activation. The understanding of Ang II signalling mechanisms remains incomplete. AT₁ receptor activation triggers a variety of intracellular systems, including tyrosine kinase-induced protein phosphorylation, production of arachidonic acid metabolites, alteration of reactive oxidant species activities, and fluxes in intracellular Ca²⁺ concentrations. AT₂ receptor activation leads to stimulation of bradykinin, nitric oxide production, and prostaglandin metabolism,

which are, in large part, opposite to the effects of the AT₁ receptor. (See: Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG.: Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2337-65. Angiotensin receptors: signalling, vascular pathophysiology, and interactions with ceramide).

Ang II is the active component of the renin-angiotensin-aldosterone system (RAAS). It plays an important physiological role in the regulation of blood pressure, plasma volume, sympathetic nervous activity, and thirst responses. Ang II also has a pathophysiological role in cardiac hypertrophy, myocardial infarction, hypertension, chronic obstructive pulmonary disease, liver fibrosis and atherosclerosis. It is produced systemically via the classical RAAS and locally via tissue RAAS. In the classical RAAS, circulating renal-derived renin cleaves hepatic-derived angiotensinogen to form the decapeptide Ang I, which is converted by ACE in the lungs to the active Ang II. Ang I can also be processed into the heptapeptide Ang-(1-7) by tissue endopeptidases.

The RAAS system is illustrated schematically in Figure 1 hereto which is based on Figure 1 in the article by Foote et al. in Ann. Pharmacother. 27: 1495-1503 (1993).

In addition to the RAAS playing an important role in the normal cardiovascular homeostasis, over activity of the RAAS has been implicated in the development of various cardiovascular diseases, such as hypertension, congestive heart failure, coronary ischemia and renal insufficiency. After myocardial infarction (MI), RAAS becomes activated. Specifically the AT₁ receptor seems to play a prominent role in post-MI remodelling, since AT₁ receptor expression is increased after MI and in left ventricular dysfunction. Therefore drugs that interfere with RAAS, such as ACE inhibitors and AT₁ receptor antagonists have been shown to be of great therapeutic benefit in the treatment of such cardiovascular disorders.

The anatomic coincidence between the expression of ACE and the AT₁ receptors with normal and pathological expressions of collagen formation is evident. High-density ACE and Ang II receptor binding are markers of active collagen turnover. Alfa-SMA-containing, fibroblast-like cells, found within valve leaflets, adventitia, and various sites of fibrous tissue formation, express genes encoding for ACE, AT₁ receptors, and fibrillar collagens. MyoFbs could therefore be considered a "metabolic entity" regulating their own collagen turnover.

ACE binding density is related primary to the presence of myoFbs. The disappearance of ACE-positive cells or a reduction in their absolute number would reduce ACE binding density at sites of fibrosis. Such is the case with old sarcoid granulomas. Both ACE and Ang II receptor binding densities in the infarcted rat heart remain high for many months after the MI, as does ACE activity. Each is in the keeping with the persistence of myoFbs at the infarcted site. (Weber, K.T.: Extracellular Matrix Remodelling in Heart Failure: A Role for De Novo Angiotensin II Generation. Circulation, Volume 96(11), December 2, 1997, 4065-4082.)

For heart, kidneys, lungs and liver alike, fibrosis represents a common pathway to their failure. Understanding pathophysiologic mechanisms involved in organ fibrosis are therefore of considerable interest, particularly given the potential for protective pharmacological strategies. Tissue repair involves inflammatory cells, including members of the monocyte/macrophage lineage, integral to initiating the repair process; and myofibroblasts, phenotypically transformed interstitial fibroblasts, responsible for collagen turnover and fibrous tissue formation. Each of these cellular events in the microenvironment of repair are associated with molecular events that lead to the de novo generation of Ang II. In an autocrine/paracrine manner, this peptide regulates expression of Transforming growth factor beta 1, TGF-beta 1, via angiotensin (AT₁) receptor-ligand binding. It is this cytokine that contributes to phenotypic conversion of fibroblasts to myofibroblasts (myoFb) and regulates myofibroblast turnover of collagen. ACE inhibition or AT₁ receptor antagonisms each prevent many of these molecular and cellular responses that eventuate in fibrosis and therefore have been found to be protective interventions.

(See: Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol. 1997 Sep;17(5):467-91 and references therein).

Ang II may regulate tissue fibrosis via the activation of mesenchymal cells. For example, Ang II stimulates the proliferation of cardiac fibroblasts *in vitro* via activation of AT₁. The presence of AT₁ receptors has also been demonstrated on cardiac fibroblasts *in vitro*. Most of the profibrotic effects of Ang II appear to be mediated via this receptor; however, increased AT₂ expression on cardiac fibroblasts has been detected in hypertrophied human heart, and the balance between the expression of these two subtypes may be critical in determining the response to Ang II. (See: Am. J. Respir. Crit. Care Med., Volume 161, Number 6, June 2000, 1999-2004 Angiotensin II Is Mitogenic for Human Lung Fibroblasts via Activation of the Type 1 Receptor

Richard P. Marshall, Robin J. McAnulty, and Geoffrey J. Laurent and references therein).

The Ang II receptors can be distinguished according to inhibition by specific antagonists. AT₁ receptors are selectively antagonized by biphenylimidazoles, such as Losartan, whereas tetrahydroimidazopyridines specifically inhibit AT₂ receptors. The AT₂ receptor may also be selectively activated by CGP-42112A. This is a hexapeptide analog of Ang II, which may also inhibit the AT₂ receptor, depending on concentration). Two other angiotensin receptors have been described: AT₃ and AT₄ subtypes.

In rodents, the AT₁ receptor has two functionally distinct subtypes, AT_{1A} and AT_{1B}, with >95% amino acid sequence homology.

The second major angiotensin receptor isoform is the AT₂ receptor. It has low amino acid sequence homology (~34%) with AT_{1A} or AT_{1B} receptors. Although the exact signaling pathways and the functional roles of AT₂ receptors are unclear, these receptors may antagonize, under physiological conditions, AT₁-mediated actions inhibiting cell growth and by inducing apoptosis and vasodilation. The exact role of AT₂ receptors in cardiovascular disease remains to be defined.

Other receptors for Ang II besides AT₁ and AT₂ are known and are generally referred to as AT_{atypical} (see Kang et al., Am. Heart J. 127: 1388-1401 (1994)).

The suppression of Ang II's effects has been used therapeutically, for example in the management of hypertension and heart failure. This has been achieved in a number of ways: by the use of renin inhibitors which block the conversion of angiotensinogen to Ang I (the precursor to Ang II); by the use of angiotensin converting enzyme inhibitors (ACE-I) that block the conversion of Ang I to Ang II (and also block bioconversion of bradykinin and prostaglandins); by the use of anti-Ang II -antibodies; and by the use of Ang II -receptor antagonists.

Beta blockers are most commonly used in treatment of arrhythmias. Anti-arrhythmic drugs have had limited overall success and calcium channel blockers can sometimes induce arrhythmias. No single agent shows superiority, with the possible exception of amiodarone. Short-term anti-arrhythmic benefit has been found to be offset by, depending on the specific drug, neutral or negative effects on mortality (Sanguinetti

+47 23186019

-5-

PN0411

MC and Bennett, PB: Anti-arrhythmic drug target choices and screening. Circulation 2003, 93(6): 491-9257-263). Clearly better anti-arrhythmic drugs are needed.

A publication in Lancet (Lindholm, LH et al. Effect of Losartan on sudden cardiac death in people with diabetes: data from the LIFE study, The Lancet, 2003, 362: 619-620) revealed that AT₁ receptor antagonists in addition of being generally favourable to patients with CHF, also reduce the incidence of sudden cardiac death. There exist a few studies showing that AT₁ antagonists have an anti-arrhythmia effect on arrhythmias induced by myocardial infarct or in reperfusion after ligation of LAD (Harada K et al. Angiotensin II Type 1a Receptor is involved in the occurrence of reperfusion arrhythmias, Circulation, 1998, 97:315-317, Ozer MK et al. Effects of Captopril and Losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats, Pharmacological research, 2002, 45 (4), 257-263, Lynch JJ et al. EXP3174, The AII antagonist human metabolite of Losartan, but not Losartan nor the Angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic arrhythmias in a canine model of recent myocardial infarction, JACC, 1999, 34 876-884).

Ang II may be turned into potent antagonists or partial antagonists by changes in their amino acid composition. For instance substituting phenylalanine in position 8 with isoleucine and aspartic acid in position 1 with sarcosine changes the peptide into a potent antagonist.

The specificity towards the AT₁ receptor may be increased by cyclisation or bridging of the amino acids in position 3 and 5. Similarly introducing sarcosine in position 1 and glycine in position 8 makes the peptide into a AT₁ selective antagonist (See RC Speth. Sarcosine11, glycine8 angiotensin II is an AT₁ angiotensin II receptor subtype selective antagonist). Regulatory peptides 115 (2003) 203-209)

As mentioned above, the natural ligand to the AT₁ receptor is the octapeptide AngII, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, which binds to the AT₁ receptor in the nano-mole range.

When modifying a naturally binding ligand to a receptor by the binding of a moiety, in particularly with moieties that are relatively large and relatively bulky, the affinity of the peptide vector is frequently compromised.

+47 23186019

- 6 -

PN0411

Description of related art

WO 98/18496 (Nycomed Imaging AS) discloses contrast agents comprising a vector-linker-reporter construct where the vector comprises angiotensin or a peptidic angiotensin derivative.

US patent 4411881 (New England Nuclear Corporation) reads on stabilization of radio-labelled compounds. Examples of radio-labelled compounds include e.g. Angiotensin II (5-L-isoleucine) [tyrosyl-¹²⁵I]-(monoiodinated).

Summary of invention

A first objective with the present invention is to provide pharmaceuticals useful in the treatment of heart failure, cardiac arrhythmias and other diseases where fibrosis is prominent such as in COPD, liver fibrosis, and atherosclerosis comprising a peptidic moiety, Ang I or a derivative thereof, that is converted by ACE to a targeting imaging agent and a targeting pharmaceutical for treatment of disease, that demonstrate a higher binding affinity to the AT₁ receptor than the native octapeptide Ang II. The pharmaceutical should demonstrate antagonistic activity.

A second objective with the present invention is to provide pharmaceuticals useful in the diagnosis of heart failure and other diseases where fibrosis is prominent such as in COPD, liver fibrosis, and arteriosclerosis comprising a targeting moiety incorporating an imageable moiety. The imageable moiety can be any imageable moiety which when administered to a subject can generate an image of at least a part of said subject to which said pharmaceutical has distributed, e.g. by radio imaging, SPECT, PET, MRI, X-ray, optical imaging (OI), ultrasound (US), electrical impedance or magnetometric imaging modalities. The peptide part of the pharmaceuticals of the present invention is Ang I or a derivative thereof, which is converted into Ang II or a derivative thereof by ACE *in vivo*. After cleavage with ACE the pharmaceutical is a targeting imaging agent and/or a targeting pharmaceutical for treatment of disease. The targeting moiety incorporating the imageable moiety demonstrate a higher binding affinity to the AT₁ receptor than the Ang II and preferably act as an antagonist although a weak agonistic activity may also be acceptable.

The new pharmaceuticals can hence be used sequentially or concurrently as a therapeutic agent when carrying a suitable imageable moiety for diagnostic imaging.

+47 23186019

-7-

PN0411

Further objectives comprise providing methods of treatment of hypertension, fibrosis, COPD and related diseases and methods of imaging of heart failure and fibrosis and also methods of monitoring of progression of treatment for such diseases and disorders as well as for related vascular diseases and disorders. The invention further provides novel pharmaceutical compositions and precursors for the preparation of diagnostic agents. Kits of diagnostic agents, in particular kits for the preparation of radiopharmaceutical diagnostic agents are also provided.

The pharmaceuticals of the invention comprise a peptide V, optionally a linker L and a moiety Z and can be visualised by formula (I)



wherein

V denotes a peptide with a binding sequence $-\text{X}^1-\text{X}^2-\text{Val}-\text{Tyr}-\text{Ile}-\text{His}-\text{Pro}-\text{X}^8-\text{X}^9-\text{X}^{10}$,

L denotes a bond or a linker,

Z denotes a group that optionally can carry an imaging moiety M,

X^1 denotes an amino acid,

X^2 denotes Arg, N-alkylated Arg, or a mimetic of Arg,

X^8 denotes Gly or Phe or an amino acid containing an aromatic or aliphatic side-chain,

X^9 and X^{10} denote, independent of each other, Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys and where X^8 , X^9 and X^{10} together constitute an ACE cleavage site

and wherein the residues Val and Ile at position 3 and 5 respectively may optionally be replaced with amino acids capable of forming a bridge,

Z forms a bond with the amino acid X^1 optionally through the linker L, and

M where present denotes an imageable moiety capable of detection either directly or indirectly in a diagnostic imaging procedure.

In areas of collagen formation, both in normal and pathological collagen formation, ACE and AT_1 receptor expressions are increased. The pharmaceuticals of the present invention comprise a peptidic moiety of Ang I or a derivative thereof including an ACE cleavage site. This Ang I is converted into Ang II by cleavage by ACE *in vivo*. We have surprisingly found that such Ang II resulting from the cleavage of Ang I with ACE and which is substituted in specific positions of the peptide not only retains its binding capability but surprisingly increases its affinity for the Ang II receptors, in particular to the AT_1 receptor.

The pharmaceuticals of the present invention are converted into their active form, where the peptidic moiety is an Ang II analogue, by ACE on a site where the AT₁ receptor density is elevated. The co-localisation of increased ACE and AT₁ receptor densities in the sites of fibrous tissue formation give the present pharmaceutical the advantage that the active targeting form is formed at the site where the AT₁ receptor density is high. This prevents unwanted systemic effects in other parts of the body since the active Ang II analogues become AT₁ receptor bound on the site of formation and are not circulated.

The pharmaceuticals of the present invention show a better signal noise level i.e. heart to liver ratio, in imaging.

Detailed description of the invention

The invention is described in the patent claims. Specific features of the invention are outlined in the following detailed description and the Examples.

In the targeting moiety of the formula (I) above V denotes the peptide sequence -X¹-X²-Val-Tyr-Ile-His-Pro-X⁸-X⁹-X¹⁰.

In the peptide V of formula (I) the amino acids are L-amino acids as in the native Ang I where not defined otherwise.

The three letter abbreviations used for the amino acids have the following meaning:

Arg	- Arginine
Asp	- Aspartic acid
Cys	- Cysteine
Hcy	- Homocysteine
Gly	- Glycine
Sar	- Sarcosine
Val	- Valine
Tyr	- Tyrosine
Ile	- Isoleucine
Glu	- Glutamic acid
Lys	- Lysine
His	- Histidine
Ala	- Alanine

Leu - Leucine
Ile - Isoleucine
Met - Methionine
Trp - Tryptophan
Pro - Proline
Phe - Phenylalanine
Abu - 2-Amino-butyric acid
Nva - 2-Amino-pentanoic acid
Nle - 2-Amino-hexanoic acid
Phg - 2-Amino-2-phenyl acetic acid
Hph - 2-Amino-4-phenyl butanoic acid
Bip - 2-Amino-3-biphenyl propionic acid
Nal - 2-Amino-3-naphtyl propionic acid
Cha - 2-Amino-3-cyclohexyl propionic acid

The amino acids of V preferably are independently selected such that

X^1 denotes $-NY_1-(CH_2)_m-CO-$ where m is an integer from 1 to 10 and Y_1 is H or an alkyl or aryl containing substituent, most preferred Gly

X^2 denotes Arg or N-Methyl-Arg or the Arg mimetics Phe[4-guanidino] and Gly-4-piperidyl[N-amidino],

X^6 denotes Phe, Phg, Hph, Bip, Ala, Gly, Tyr, His, Trp or Nal; most preferred Phe,

X^9 and X^{10} denote, independent of each other, Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys

Still further preferred are pharmaceuticals where X^1 denotes Gly, X^2 denotes Arg and X^6 denotes Phe, X^9 denotes Phe, Leu or Ala and X^{10} denotes Phe, Ala or His.

If the amino acids at position 3 and 5 are selected to form a bridging unit the bridge preferably containing a $-CH_2-CH_2-$, $-S-CH_2-$, $-S-CH_2-S-$, lactam or $-S-S-$ unit.


More preferred the covalent bond is a disulfide bond formed by oxidation of 2 cysteine or homocysteine pairings.

Examples of suitable linkers L are described in WO 98/18496 and in WO 01/77145 (pages 23 to 27) the content of which are hereby incorporated by reference. L may preferably represent a polyalkylene glycol unit such as polyethylene glycol (PEG) and polypropylene glycol (PPG), a carbohydrate, dextran or 1 to 10 amino acids. The linker may also serve as a biomodifier as described e.g. in WO 03/006491.


The linker L may also be derived from alkylamines or arylamines preferably compounds of the formula $\text{NH}-(\text{CH}_2)_m$ - optionally combined with $-\text{CO}-(\text{CH}_2)_m-\text{CO}-$ where m denotes a positive integer from 1 to 10.

The linker may also comprise one or more units of PEG as defined in formula IV hereinafter wherein n is an integer from 1 to 10.

Most preferred are linkers defined by formula (V) and (VI):



Formula (V)



Formula (VI)

The moiety Z comprises a non-peptidic moiety having a molecular weight of more than 50 D (Dalton), more preferably between 100 and 1000 D and still more preferably between 300 to 700 D. The moiety Z can be any pharmaceutically acceptable chemical entity provided that the resulting targeting moiety, after cleavage with ACE, of formula (I) demonstrates a higher binding affinity to the AT₁ receptor than the native ligand Ang II. More specifically Z denotes an organic group having a suitable functional group such that Z can be reacted either with the linker L or directly with the peptide V to form a stable covalent bond.

Z can denote a straight or branched hydrocarbonyl group optionally containing one or more double or triple bonds and optionally substituted by halogen, oxygen, sulphur or phosphorous atoms or optionally including heteroatoms such as oxygen, nitrogen or sulphur. More specifically the hydrocarbonyl group can denote a substituted or unsubstituted alkyl, alkenyl, alkynyl groups having a molecular weight of at least 50 D.

+47 23186019

-11-

PN0411

Z can also denote one or more linked carbocyclic residues comprising monocyclic, bicyclic or tricyclic ring systems which can be saturated, partially unsaturated or aromatic and which can be substituted or unsubstituted and having a molecular weight of at least 50 D. Examples of such ring systems are aryl, aralkyl, cyclohexyl, adamantyl and naphthyl.

Z can further denote one or more linked heterocyclic compounds such as 5, 6, 7, 8, 9 or 10-membered ring systems which can be monocyclic, bicyclic or tricyclic and can contain one or more N, O, S and P as heteroatoms. Such ring systems can also be linked to hydrocarbyl and carbocyclic groups and defined above or fused to carbocyclic groups. Examples of such groups acridinyl, benzofuranyl, indolyl, pyridyl, piperidinyl, morphoridinyl and thienyl.

Z may also denote a polyalkylene glycol such as polyethylene glycol (PEG) and polypropylene glycol (PPG), a carbohydrate such as mono or polysaccharides all having a molecular weight in excess of 50 D. Polyalkylene glycols can additionally act as biomodifiers.

Specifically Z denotes a chelating agent such as acyclic or cyclic polyaminocarboxylates (e.g. DTPA, DTPA-BMA, DOTA and DO3A) as described e.g. in US patent 4 647 447 (Schering AG) and WO 86/02841 (Nycomed Salutar, Inc.) which is hereby incorporated by reference. Further chelating agents comprises aminethiols such as diaminedithiols, amineoximes and hydrazines and related agents as described in WO 01/77145 (see Table I therein) which is hereby incorporated by reference. The chelating agent cPN216 is particularly preferred.

For pharmaceuticals useful in treatment Z can be any entity as described above.

For pharmaceuticals useful in diagnosis and particularly in *in vivo* diagnosis the moiety Z must be able to carry the imageable moiety or moieties denoted M. By carrying is meant any form of association between the moiety Z and M such as a chemical bond, e.g. covalent bond or electrovalent or ionic bonds or by absorption or any other type of association.

In a preferred embodiment one moiety Z is covalently bound directly to X¹ forming an N-alkyl glycine unit.

Chelating agents of formula (VII) and (VIII) hereinafter are also particularly preferred.

M can be any imageable moiety. The nature of M will depend of the imaging modality utilised in the diagnosis. M must be capable of detection either directly or indirectly in an in vivo diagnostic imaging procedure. eg. moieties which emit or may be caused to emit detectable radiation (eg. by radioactive decay, fluorescence excitation, spin resonance excitation, etc.), moieties which affect local electromagnetic fields (eg. paramagnetic, superparamagnetic, ferrimagnetic or ferromagnetic species), moieties which absorb or scatter radiation energy (eg. chromophores, particles (including gas or liquid containing vesicles), heavy elements and compounds thereof, etc.), and moieties which generate a detectable substance (eg. gas microbubble generators).

A wide range of suitable imageable moieties are known from e.g. WO 98/18496, the content of which is incorporated by reference.

Imaging modalities and imageable moieties M are described in more detail hereinafter:

In a first embodiment, the pharmaceuticals of formula (I) comprises a moiety Z carrying one or more imageable moieties M useful in the Radio and SPECT imaging modality. Preferably M is a gamma emitter with low or no alpha- and beta-emission and with a half-life of more than one hour. Preferred groups M are the radionuclides ^{67}Ga , ^{111}In , ^{123}I , ^{125}I , ^{131}I , $^{81\text{m}}\text{Kr}$, ^{99}Mo , $^{99\text{m}}\text{Tc}$, ^{201}Tl and ^{133}Xe . Most preferred is $^{99\text{m}}\text{Tc}$.


When M denotes a metallic radionuclide then Z denotes a chelating agent suitable for forming a stable chelate with M. Such chelating agents are well known from the state of art and typical examples of such chelating agents are described in Table I of WO 01/77145.

Particularly preferred are chelating agents of formula (VII):

+47 23186019

-13-

PN0411




(VII)

wherein:

each R^1 , R^2 , R^3 and R^4 is independently H or C_{1-10} alkyl, C_{3-10} alkylaryl, C_{2-10} alkoxyalkyl, C_{1-10} hydroxyalkyl, C_{1-10} alkylamine, C_{1-10} fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

More particularly preferred are chelating agents of formula (VII) where R^1 , R^2 and R^3 are hydrogen or methyl groups and R^4 is an alkylamine group, most specifically a compound of formula (VIII), herein denoted cPN216.



Formula (VIII)

Most preferred for Z is when the chelating agent is cPN216 then the imaging moiety M is ^{99m}Tc .

Non-metal radionuclides such as ^{123}I , ^{125}I and ^{131}I may be covalently linked to the moiety Z by a substitution or addition reaction well known from the state of art.

In a second embodiment, the pharmaceuticals of formula (I) comprises a moiety Z carrying one or more imageable moieties M useful in the PET imaging modality. M then denotes a radioemitter with positron-emitting properties. Preferred groups M are the radionuclides ^{11}C , ^{18}F , ^{68}Ga , ^{13}N , ^{15}O and ^{82}Rb . ^{18}F is specifically preferred.

47 23186019

-14-

PN0411

When M denotes a metallic radionuclide then Z denotes a chelating agent suitable for forming a stable chelate with M. Such chelating agents are well known from the state of art and typical examples of such chelating agents are described in Table I of WO 01/77145 and to the previous part on Radio and SPECT imaging.

In another preferred embodiment Z is the DOTA chelating agent and M is ^{68}Ga which can be readily introduced in to the chelate using microwave chemistry.

Non-metal radionuclides such as ^{18}F may be covalently linked to the moiety Z by a substitution or addition reaction well known from the state of art and also described eg. in WO03/080544 which is hereby incorporated by reference.

In a third embodiment, the pharmaceuticals of formula (I) comprises a moiety Z carrying one or more imageable moieties M useful in the MR imaging modality. M here denotes a paramagnetic metal such those mentioned in US patent 4 647 447, Gd^{3+} , Dy^{3+} , Fe^{3+} and Mn^{2+} are particularly preferred and Z denotes a chelating agent, in particular a chelating agent such as acyclic or cyclic polyaminocarboxylates (e.g. DTPA, DTPA-BMA, DOTA and DO3A) as described e.g. in US patent 4 647 447 and WO 86/02841. M may also denote metal oxides such as superparamagnetic, ferrimagnetic or ferromagnetic species which are absorbed by Z, e.g. such that Z function as a coating to the metal oxide. Metal oxides for use as MR imaging agents are described e.g. in US patent 6 230 777 which is hereby incorporated by reference.

In a fourth embodiment the pharmaceuticals of formula (I) comprises a moiety Z carrying one or more imageable moieties M useful in the X-ray imaging modality. M here denotes a heavy metal such as W, Au and Bi preferably in the form of oxides which may be absorbed to Z. Iodinated aryl derivatives are particularly well known as X-ray contrast agents, e.g. IopamironTM and OmnipaqueTM. These agents can be linked via their amide or amine functions to the peptide V.


Ultrasound imaging agents in the form of gas filled microvesicles can be utilised in the imaging of receptors e.g. when they are functionalised for binding to a peptide as described in the state of art e.g. in WO98/18500.

Use of imaging agents for optical imaging with affinity for biological targets can be provided following the procedures in the state of art e.g. as described in WO

96/17628 of Schering AG which is herewith incorporated by reference.

The pharmaceutical of formula (I) may be further modified by the attachment of one or more biomodifier groups such as polyalkylene glycol unit e.g. polyethylene glycol (PEG) and polypropylene glycol (PPG). Examples of biomodifier groups are described in WO 03/006491 the content of which is hereby incorporated by reference. The biomodifier groups can be linked to any position in the V and L groups of formula (I) as long as it does not significantly affect in a negative way the cleavage by ACE or the cleaved compound's ability to link to the target receptor.

The biomodifier is preferably based on a monodisperse PEG building block comprising 1 to 10 units of said building block, said biomodifier having the function of modifying the pharmacokinetics and blood clearance rates of the said agents. In a preferred embodiment of this invention, the compound of formula IV, represents a biomodifier unit comprised of polymerisation of the monodisperse PEG-like structure, 17-amino-5-oxo-6-aza-3,9,12,15-tetraoxaheptadecanoic acid.



wherein n equals an integer from 1 to 10 and where the C-terminal unit forms an amide bond.


Examples of pharmaceuticals of formula (I) are represented by:

Compounds of the formula (II) and (III):



where m is an integer of between 1 and 5 and Z, X¹, X², X⁸, X⁹ and X¹⁰ are as defined previously.


Compounds defined by formula Va and VIa:



+47 23156019


-16-

PN0411



where Z and V are as defined previously.

Compounds of the formula (IX):



where Y² is alkyl, aryl or a short PEG containing moiety and Y² is preferably -CH₂-CH₂-CH₂- and X⁸, X⁹ and X¹⁰ is as defined above.

As noted above, for use in in vivo diagnosis the chelates of these compounds with ^{99m}Tc or ¹⁸F are particularly preferred.

The pharmaceutical of formula (I) are preferably administered as a pharmaceutical formulation comprising the pharmaceuticals of formula (I) in a form suitable for administration to a mammal, such as a human. The administration is suitable carried out by injection or infusion of the formulation such as an aqueous solution. The formulation may contain one or more pharmaceutical acceptable additives and/or excipients e.g. buffers; solubilisers such as cyclodextrins; or surfactants such as Pluronic, Tween or phospholipids. Further, stabilisers or antioxidants such as ascorbic acid, gentisic acid or para-aminobenzoic acid and also bulking agents for lyophilisation such as sodium chloride or mannitol may be added.

In a still further aspect a kit for the preparation of a radiopharmaceutical composition of formula (I) comprising a peptide-chelate conjugate and a reducing agent is provided. Preferably the reducing agent of the kit is a stannous salt. The kit may also

+47 23186019

-17-

PN0411

comprise one or more stabilisers, antioxidants, bulking agents for lyophilisation and solubilisers.

General procedures for the preparation of the pharmaceuticals and its precursors

The abbreviations used have the following meanings:

Fmoc: 9-fluorenylmethoxycarbonyl

Boc: *t*-butoxycarbonyl

*t*Bu: *t*-butyl

Trt: trityl

Pmc: 2,2,5,7,8-pentamethylchroman-6-sulfonyl

TFA: trifluoroacetic acid

HBTU: O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate

DMF: dimethylformamide

NMP: N-methylpyrrolidone

TIS: triisopropylsilane

NHS: N-hydroxysuccinimidyl

NMM: N-methylmorpholine

RP-HPLC: reversed phase high pressure liquid chromatography

Wang resin: *p*-benzyloxybenzyl alcohol resin

Synthesis of V:

The peptides V of the present invention can be synthesised using all the known methods of chemical synthesis but particularly useful is the solid-phase methodology of Merrifield employing an automated peptide synthesizer (J. Am. Chem. Soc., 85: 2149 (1964)). Typically, the desired sequences are assembled by solid-phase peptide synthesis. Standard procedures for the synthesis strategy employed for the examples of this invention are described in E. Atherton & R.C. Sheppard, "Solid phase peptide synthesis: a practical approach", 1989, IRL Press, Oxford.

For example, a resin with an acid-labile linker group, to which the desired amino-protected C-terminal amino acid residue has been esterified, is used. The amino protecting group is then removed and the second amino acid in the sequence is coupled using a suitable condensation reagent. Amino acids with semi-permanent amino protecting groups and permanent protecting groups for the functional side chains are employed. Amino-deprotection and coupling cycles are then repeated in alternating steps until the sequence of interest is assembled.

+47 23186019

-18-

PN0411

Alternatively, the peptides V can be synthesised through solution peptide synthesis methods known in the art, either in a step-wise manner from the carboxyl terminus and/or through the application of segment condensation or ligation methods, employing comprehensive or minimal protection strategies. Combined solution-solid phase segment condensation approaches can also be applied.

Generally, the reactive side-chain groups present (for example amino, hydroxyl, guanidino and carboxyl groups) will be protected during overall synthesis as indicated above. A wide choice of protecting groups for amino acids is known (see, e.g., Greene, T.W. & Wuts, P.G.M. (1991) Protective groups in organic synthesis, John Wiley & Sons, New York). Amino protecting groups which may be employed include 9-fluorenylmethoxycarbonyl (Fmoc) and *t*-butyloxycarbonyl (Boc). Side-chain protecting groups which may be employed include *t*-butyl (*t*Bu), trityl (Trt), Boc, and 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc). It will be appreciated that a wide range of other such groups are known in the art.

Finally the permanent side-chain protecting groups are removed and the peptide is cleaved from the resin, usually simultaneously through treatment with a suitable acidic reagent, e.g. trifluoroacetic acid (TFA).

Conjugation of L to V:

L can be conjugated to V using all the known methods of chemical synthesis. Particularly useful is the nucleophile substitution reaction where a leaving group on the peptide N-terminus is replaced by a nucleophilic group on L. Such a leaving group may be a bromide attached in alpha position to a carbonyl group, and such a nucleophile may be nitrogen.

Conjugation of Z to V or to L:

Z can be conjugated directly to V using the same methods as for the conjugation of L to V. In the case where Z is attached to V via L any methods of chemical synthesis may be used in the conjugation of Z and L. Particularly useful is amide bond formation.

+47 23186019

-19-

PN0411

SEQUENCE LISTING

<110> Amersham Health AS

<120> Pharmaceutical compounds

<130> PN0411

<160> 2

<170> PatentIn version 3.1

<210> 1

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> Synthesised peptide

<220>

<221> Misc_feature

<222> (1)..(1)

<223> Any amino acid

<220>

<221> Misc_feature

+47 23186019

-20-

PN0411

<222> (2)..(2)

<223> Arg, N-acylated Arg or a mimetic thereof

<220>

<221> Misc_feature

<222> (8)..(8)

<223> Gly, Phe or an amino acid containing an aromatic or aliphatic side-chain

<220>

<221> Misc_feature

<222> (9)..(9)

<223> Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys

<220>

<221> Misc_feature

<222> (10)..(10)

<223> Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys

<400> 1

Xaa Xaa Val Tyr Ile His Pro Xaa Xaa Xaa

1

5

10

+47 23186019

-21-

PN0411

<210> 2

<211> 10

<212> PRT

<213> Angiotensin I sequence

<400> 2

Gly Arg Val Tyr Ile His Pro Phe His Leu

1

5

10


+47 23186019

-22-

PN0411

ExamplesExample 1 Ang I analogue for ^{99m}Tc labelling

cPn216-Gly-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH



A peptide analogue of Ang I was synthesised on an Applied Biosystems 433A peptide synthesizer starting with 0.1 mmol Fmoc-Leu-SASRIN resin. An excess of 1 mmol pre-activated amino acids (using HBTU; O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate) was applied in the coupling steps up to Arginine. The N-terminus was bromoacetylated using 0.5 mmol bromoacetic anhydride in DMF for 60 minutes. The bromoacetylated resin was then treated with a solution of 0.1 mmol cPn216 and 0.2 N-methylmorpholine dissolved in dimethylformamide for 60 minutes.

The simultaneous removal of side-chain protecting groups and cleavage of the peptide from the resins was carried out in 5 mL trifluoroacetic acid (TFA) containing 2.5 % triisopropylsilane and 2.5 % water for 60 minutes. TFA was removed in vacuo, diethyl ether added to the residue and the precipitated product washed with diethyl ether and air-dried.

Purification by preparative RP-HPLC (20-35 % B over 40 min, where A = H₂O/0.1 % TFA and B = CH₃CN/0.1 % TFA, at a flow rate of 10 mL/min on a Vydac C18 250 x 21.20 mm column) of the product afforded 3 mg pure chelate-peptide conjugate. The product was analysed by analytical HPLC (conditions: Gradient, 20-35 % B over 20 min where A = H₂O/0.1 % TFA and B = CH₃CN/0.1 % TFA; flow, 1 mL/min; column, Vydac C18 25 x 4.6 mm; detection, UV 214 nm; product retention time 14.9 min). Further product characterisation was carried out using electrospray mass spectrometry (MH⁺ calculated, 1564.9; MH⁺ found, 1564.9).



+47 23186019

-23-

PN0411

Claims

1. A pharmaceuticals characterized by general formula (I)



wherein

V denotes a peptide with a binding sequence $-X^1-X^2\text{-Val-Tyr-Ile-His-Pro-}X^8\text{-}X^9\text{-}X^{10}$,

L denotes bond or a linker,

Z denotes a group that optionally can carry an imaging moiety M,

n is 0 or 1,

X^1 denotes an amino acid,

X^2 denotes Arg, N-alkylated Arg, or a mimetic of Arg,

X^8 denotes Gly or Phe or an amino acid containing an aromatic or aliphatic side-chain,

X^9 and X^{10} denote, independent of each other, Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys and where X^8 , X^9 and X^{10} together constitute an ACE cleavage site

and wherein the residues Val and Ile at position 3 and 5 respectively may optionally be replaced with amino acids capable of forming a bridge,

Z forms a bond with the amino acid X^1 optionally through the linker L, and

M where present denotes an imageable moiety capable of detection either directly or indirectly in a diagnostic imaging procedure.

2. A pharmaceutical according to claim 1 where X^8 denotes an amino acid with an aromatic or aliphatic side chain.
3. A pharmaceutical according to claims 1 and 2 where X^8 denotes Phe, Phg, Hph, Bip, Ala, Gly, Tyr, His, Trp or Nal; most preferred Phe.
4. A pharmaceutical according to claims 1 and 3 where X^9 and X^{10} denote, independent of each other, Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys
5. A pharmaceutical according to claims 1-4 wherein M is not present.

+47 23186019

-24-

PN0411


6. A pharmaceutical according to claims 1-4 wherein M is an in vivo imagable moiety.
7. A pharmaceutical of the preceding claims wherein the amino acids are L-amino acids.
8. A pharmaceutical of the preceding claims where the amino acids of X^1 , X^2 , X^8 , X^9 , X^{10} are independently selected from
 X^1 denoting $-NY_1-(CH_2)_m-CO-$ where m is an integer from 1 to 10 and Y_1 is H or an alkyl or aryl containing substituent,
 X^2 denoting Arg or N-Methyl-Arg or the Arg mimetics Phe[4-guanidino] and Gly-4-piperidyl[N-amidino]
 X^8 denoting Phe, Phg, Hph, Bip, Nal, Gly, Ala, His, Trp or Tyr
 X^9 denoting Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys and
 X^{10} denoting Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys.
9. A pharmaceutical according to claim 8 wherein the amino acid of X^1 , X^2 , X^8 , X^9 , X^{10} are independently selected from
 X^1 denoting Gly
 X^2 denoting Arg or N-Methyl-Arg
 X^8 denoting Phe
 X^9 denoting Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys and
 X^{10} denoting Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys.
10. A pharmaceutical of the preceding claims wherein the amino acids at positions 3 and 5 are selected to form a bridging unit where the bridging unit contain a $-CH_2-CH_2-$, $-S-CH_2-$, $-S-CH_2-S-$, lactam or $-S-S-$ unit.
11. A pharmaceutical according to claim 10 wherein the bridging unit is a disulfide bond formed by oxidation of two Cys or homocysteine pairings.
12. A pharmaceutical according to the preceding claims further comprising one or more biomodifier groups are attached to any positions of the V and L groups of formula (I)

+47 23186019

-25-


PN0411

13. A pharmaceutical according to claim 12 where the biomodifier groups are selected from polyalkylene glycol units, specifically from polyethylene glycol (PEG) and polypropylene glycol (PPG) units.
14. A pharmaceutical according to claims 12 and 13 where the biomodifier groups are selected from compounds of the formula (IV)



wherein n equals an integer from 1 to 10 and where the C-terminal unit is an amide moiety.

15. A pharmaceutical according to claims 1-14 wherein L denotes a polyalkylene glycol unit such as polyethylene glycol (PEG) and polypropylene glycol (PPG), a carbohydrate, dextran or 1 to 5 amino acids
16. A pharmaceutical according to claims 1-14 wherein L is derived from alkylamines or arylamines.
17. A pharmaceutical according to claim 16 wherein L denotes compounds of the formula $\text{NH}-(\text{CH}_2)_m-$ optionally combined with $-\text{CO}-(\text{CH}_2)_m-\text{CO}-$ where m denotes a positive integer from 1 to 10.
18. A pharmaceutical according to claims 1 to 14 wherein L comprises one or more units of PEG of formula (IV)




wherein n is an integer from 1 to 10.

+47 23186019


-26-

PNO411

19. A pharmaceutical according to claims 1-14 wherein L denotes compounds of formula (V) and (VI)




Formula (V)



Formula (VI)

20. A pharmaceutical according to the preceding claims wherein Z denotes a chelating agent.

21. A pharmaceutical according to claim 20 wherein Z denotes the chelating agent of formula (VII)




(VII)

wherein:

each R^1 , R^2 , R^3 and R^4 is independently H or C_{1-10} alkyl, C_{3-10} alkylaryl, C_{2-10} alkoxyalkyl, C_{1-10} hydroxyalkyl, C_{1-10} alkylamine, C_{1-10} fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

22. A pharmaceutical according to claim 21 wherein Z denotes a chelating agent of formula (III)



Formula (VIII)

23. A pharmaceutical according to any of the preceding claims wherein M represents an imageable moiety for the use in diagnosis particularly in *in vivo* diagnosis comprising a moiety which emit or cause to emit detectable radiation, a moiety which affect local electromagnetic fields, moieties which absorb or scatter radiation energy, heavy metals and compounds thereof and moieties which generate a detectable substance.
24. A pharmaceutical according to claim 23 wherein M represents a gamma emitting moiety for Radio or SPECT imaging comprising ^{67}Ga , ^{111}In , ^{123}I , ^{125}I , ^{131}I , $^{81\text{m}}\text{Kr}$, ^{98}Mo , $^{99\text{m}}\text{Tc}$, ^{201}Tl and ^{133}Xe .
25. A pharmaceutical according to claim 24 wherein M represents $^{99\text{m}}\text{Tc}$.
26. A pharmaceutical according to claim 23 wherein M represents a radio emitter with positron emitting properties for PET imaging comprising ^{11}C , ^{18}F , ^{68}Ga , ^{13}N , ^{15}O and ^{82}Rb .
27. A pharmaceutical according to claim 26 wherein M represents ^{18}F or ^{68}Ga .
28. A pharmaceutical according to claim 23 wherein M represents a paramagnetic metal comprising Gd^{3+} , Dy^{3+} , Fe^{3+} and Mn^{2+} or a metal oxide such as a superparamagnetic, ferromagnetic or ferromagnetic species.
29. A pharmaceutical according to claim 23 wherein M represents a paramagnetic metal comprising Gd^{3+} , Dy^{3+} , Fe^{3+} and Mn^{2+} and Z denotes a chelating agent of the group consisting of acyclic or cyclic

+47 23136019

-28-

PN0411

polyaminocarboxylates, specifically DTPA, DTPA-BMA, DOTA and DO3A.

30. A pharmaceutical according to claim 30 where M denotes ^{99m}Tc .
31. Pharmaceutical precursors for the preparation of diagnostic agents of the formula (I) where M is not present
32. Preparation of pharmaceuticals of claim 1 where an imageable moiety M reacted with a pharmaceutical precursor of claim 30.
33. Pharmaceuticals of claim 1 useful for the monitoring of therapeutic treatment
34. Pharmaceutical formulation comprising a pharmaceuticals of formula (I) of claim 1 together with one or more pharmaceutical acceptable additives and/or excipients.
35. Use of pharmaceuticals of claim 1 for the treatment of heart failure, cardiac arrhythmias and other diseases where fibrosis is prominent specifically COPD, liver fibrosis and arterosclerosis.
36. Use of pharmaceuticals of claim 1 for the diagnosis of heart failure and other diseases where fibrosis is prominent specifically COPD, liver fibrosis and atherosclerosis.
37. Method of treatment of heart failure and other diseases where fibrosis is prominent specifically COPD, liver fibrosis and atherosclerosis by the administration of the pharmaceuticals of formula (I) in claim.
38. Method of in vivo diagnosis of heart failure and other diseases where fibrosis is prominent specifically COPD, liver fibrosis and atherosclerosis in a subject comprising administration of the pharmaceuticals of formula (I) in claim 1 followed by generation of an image of part or all of said subject.
39. Method of in vivo diagnosis of heart failure and other diseases where fibrosis is prominent specifically COPD, liver fibrosis and atherosclerosis in a subject comprising administration of the pharmaceuticals of formula (I) in claim 1 followed by generation of an image of part or all of said subject.

+47 23186019

-29-

PN0411

40. Method for the monitoring progression of the treatment of heart failure and other diseases where fibrosis is prominent specifically COPD, liver fibrosis and atherosclerosis in a subject comprising administration of pharmaceuticals of formula (I) of claim 1 followed by the generation of an image of part or all of said subject.
41. A kit for the preparation of a radiopharmaceutical composition of formula (I) comprising a peptide-chelate conjugate and a reducing agent.
42. Kit of claim 53 where the reducing agent is a stannous salt.
43. Kit of claim 53 and 54 additionally comprising one or more stabilisers, antioxidants, bulking agents for lyophilisation and solubilisers.



+47 23186019

-30-

PN0411

Abstract

A pharmaceutical of the general formula (I)

$Z-(L)_n-V$ (I)

V denotes an amino acid sequence X^1-X^2 -Val-Tyr-Ile-His-Pro- X^8 - X^9 - X^{10}

L denotes a bond or a linker

Z denotes a group that optionally can carry an imaging moiety M

X^1 denotes an amino acid,

X^2 denotes Arg or N-alkylated Arg or a mimetic of Arg ,

X^8 X^9 and X^{10} constitute an ACE cleavage site

Z forms a bond with the amino acid X^1 optionally through the linker L, and

M where denotes an imageable moiety capable of detection either directly or indirectly in a diagnostic imaging procedure.



+47 23186019

2004-03-04




FIG. 1

